Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

16 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Eligibility Peripheral T-cell Lymphoma NCT01796002

- 20.09.21 - 1 Formulaire, 2 Groupes Item, 50 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01796002

Eligibility Lymphoma NCT00275106

- 20.09.21 - 1 Formulaire, 1 Groupe Item, 18 Eléments de données, 1 Langue
Groupe Item: Criteria
Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00275106

Eligibility Lymphoma NCT00290433

- 20.09.21 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00290433

Eligibility Cutaneous T-Cell Lymphoma NCT00744991

- 17.09.21 - 1 Formulaire, 2 Groupes Item, 13 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00744991

Eligibility T-cell Non-Hodgkin's Lymphoma NCT00655668

- 06.11.18 - 1 Formulaire, 2 Groupes Item, 9 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00655668

Eligibility T-cell Lymphoma NCT00959686

- 06.11.18 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00959686

Eligibility T-Cell Lymphoma NCT00542919

- 06.11.18 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
A Study for Patients With Non-Hodgkin's Lymphomas; ODM derived from: https://clinicaltrials.gov/show/NCT00542919

Eligibility T Cell Non-Hodgkin Lymphoma NCT00684411

- 05.11.18 - 1 Formulaire, 2 Groupes Item, 20 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00684411

Eligibility Peripheral T-Cell Lymphoma NCT01482962 DRKS00004503

- 23.07.17 - 1 Formulaire, 2 Groupes Item, 26 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Responsible Party: Millennium Pharmaceuticals, Inc. ClinicalTrials.gov Identifier: NCT01482962 History of Changes Other Study ID Numbers: C14012 2011-003545-18 ( EudraCT Number ) DRKS00004503 ( Registry Identifier: Germany (DRKS) ) NL39566.068.12 ( Registry Identifier: Netherlands (CCMO) ) U1111-1181-8218 ( Registry Identifier: WHO ) Study First Received: November 28, 2011 Last Updated: March 30, 2017 Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma ODM derived from: https://clinicaltrials.gov/ct2/show/NCT01482962

Eligibility Lymphoma, T-Cell NCT00418535

- 28.04.17 - 1 Formulaire, 2 Groupes Item, 18 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00418535

Eligibility T-Cell Lymphoma NCT00161590

- 27.12.16 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue
Groupes Item: Inclusion Criteria, Exclusion Criteria
Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00161590

Eligibility T-cell Lymphoma NCT00001582

- 22.02.16 - 1 Formulaire, 2 Groupes Item, 24 Eléments de données, 1 Langue
Groupes Item: Criteria, Exclusion Criteria
Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00001582

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial